Mae gwerthwchigymru.llyw.cymru yn defnyddio cwcis sy'n hanfodol er mwyn i'r safle weithio. Rydym hefyd yn defnyddio cwcis nad ydynt yn hanfodol i'n helpu i wella gwasanaethau digidol y Llywodraeth. Mae unrhyw ddata a gesglir yn ddienw. Drwy barhau i ddefnyddio'r safle hwn, rydych yn cytuno i'n defnydd o gwcis

Derbyn ein defnydd o gwcis Gosodiadau cwcis

Gweld Hysbysiad

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad. I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Ychwanegu hysbysiad at fy Rhestr Diddordeb

Manylion yr Hysbysiad

Teitl: Community Lipid Management Service
Cyhoeddwyd gan: NHS BLMK Clinical Commissioning Group
Dyddiad Cyhoeddi: 25/11/21
Dyddiad Cau:
Amser Cau:
Math o Hysbysiad: Dyfarnu Contract
Yn Cynnwys Dogfennau: Na
Yn ESPD: Na
Crynodeb:

NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services. The Community Lipid service will offer:

• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.

• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.

• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.

• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.

• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.

• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.

• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.

• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner.

• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services.

• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.

Hysbysiad dyfarnu contract

Canlyniadau'r weithdrefn gaffael

Cyfarwyddeb 2014/24/EU - Cyfarwyddeb y Sector Cyhoeddus

Cyfarwyddeb 2014/24/EU

Adran I: Endid contractio

I.1) Enw a chyfeiriad

NHS BLMK Clinical Commissioning Group

Capability House

Silsoe, Bedfordshire

MK45 4HR

UK

Person cyswllt: Samuel Naxton

E-bost: samuel.naxton@attain.co.uk

NUTS: UKH24

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: https://www.blmkccg.nhs.uk/

I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

Community Lipid Management Service

Cyfeirnod: ACE-0490-2021-BLMK

II.1.2) Prif god CPV

85100000

 

II.1.3) Y math o gontract

Gwasanaethau

II.1.4) Disgrifiad byr

NHS BLMK Clinical Commissioning Group has awarded a contract to Evexia Health Ltd following an 'Open' procurement process to deliver a new Community Lipid Management Service.

The purpose of the Community Lipid Service is to provide a consistent, evidence-based approach to lipid management across BLMK CCG. The Community Lipid Clinic will form part of a new pathway developed with key stakeholders across BLMK, in line with evidenced-based best practice. The service will be funded to provide clinical activity to optimise lipid management in populations at very high risk of CVD (as defined by the commissioner) and provide clinical assessment for familial hypercholesterolemia in people meeting appropriate clinical criteria (as defined by the commissioner), in line with locally developed evidence-based pathways. The Community Lipid Clinic will accept referrals of people meeting the relevant clinical criteria who are registered with a GP practice in Bedfordshire, Luton and Milton Keynes Integrated Care System.

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.1.7) Cyfanswm gwerth y caffaeliad

Gwerth heb gynnwys TAW: 200 000.00 GBP

II.2) Disgrifiad

II.2.3) Man cyflawni

Cod NUTS:

UKH24


Prif safle neu fan cyflawni:

Bedfordshire, Luton and Milton Keynes

II.2.4) Disgrifiad o’r caffaeliad

NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services. The Community Lipid service will offer:

• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.

• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.

• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.

• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.

• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.

• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.

• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.

• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner.

• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services.

• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.

II.2.5) Meini prawf dyfarnu

Maes prawf ansawdd: Quality / Pwysoliad: 100%

Price / Pwysoliad:  0%

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Contract duration is for 12 months (01st January 2022 to 31st December 2022) with an option to extend for a further 12 months subject to funding, learning and benefits outcomes.

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn agored

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Na

IV.2) Gwybodaeth weinyddol

IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon

Rhif yr hysbysiad yn OJ S:

2021/S 000-018335

Section V: Dyfarnu contract

Rhif Contract: M1J4AY Community Lipid Service 2021-22

Teitl: Community Lipid Service

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

27/10/2021

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 2

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Evexia Health Ltd

2a Malzeard Road

Luton

LU3 1BD

UK

NUTS: UKH21

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Cyfanswm gwerth y contract/lot: 200 000.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section VI: Gwybodaeth ategol

VI.3) Gwybodaeth ychwanegol

Contract Duration:

12 months with an option to extend for a further 12 months subject to funding, learning and benefits outcomes.

Contract Value:

£100,000 per annum

Total contract value for a 24 month period:

£200,000

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

High Court of Justice of England and Wales

Strand

London

WC2A 2LL

UK

VI.5) Dyddiad anfon yr hysbysiad hwn

24/11/2021


Gwybodaeth a ychwanegwyd at yr hysbysiad ers iddo gael ei gyhoeddi.

Additional information added to the notice since it's publication.
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.
Prif Gyswllt: samuel.naxton@attain.co.uk
Cyswllt Gweinyddol: Dd/g
Cyswllt Technegol: Dd/g
Cyswllt Arall: Dd/g

Categorïau Nwyddau

Commodity Categories
Rhif AdnabodTeitlPrif Gategori
85100000Health servicesHealth and social work services

Lleoliadau Dosbarthu

Delivery Locations
Rhif AdnabodDisgrifiad
100DU - Holl

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

Alert Region Restrictions
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Copyright © GwerthwchiGymru